Wednesday, December 23, 2015 9:32:14 AM
12/23/15 shareholders approve three proposals, including a 1:15 reverse split of common shares effective January 7.
Shareholders also OK an increase in the number of authorized shares issuable after the reverse split and the issuance of common stock underlying convertible notes and warrants issued by the company pursuant to its November 4, 2015securities purchase agreement with five institutional investors. Under the terms of the deal, EnteroMedics will issue $23.5M in notes and warrants after the reverse split.
Net proceeds will fund commercialization activities for the vBloc neurometabolic therapy, clinical and product development, working capital and general corporate purposes.
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition • PFE • Oct 2, 2024 9:00 AM
Unitronix Corp Unveils Cryptocurrency Investment Portfolio Strategy • UTRX • Oct 2, 2024 8:40 AM
Integrated Ventures, Inc Reports Total 2024 Revenues Of $5,863,935 vs $3,862,849 for 2023. • INTV • Oct 1, 2024 9:00 AM
Nightfood Signs Letter of Intent to Acquire Los Angeles Cooking School, Integrating Automation and Robotics with World-Class Culinary Training • NGTF • Oct 1, 2024 8:30 AM
ZenaTech, Inc. (NASDAQ: ZENA) To Commence Trading Today • COOP • Oct 1, 2024 7:00 AM
Element79 Gold Corp secures loi for launching tailings reprocessing business in Arequipa, Peru • ELMGF • Oct 1, 2024 6:38 AM